Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) MRI as a Response Monitoring Tool to Neoadjuvant Abiraterone
Conditions: High Risk Prostate Carcinoma; Prostate Cancer Interventions: Drug: Abiraterone acetate; Drug: Prednisone; Drug: Hyperpolarized [1-13C] pyruvate (HP 13C); Procedure: Magnetic Resonance Imaging (MRI); Procedure: Non-investigational radical prostatectomy (RP); Procedure: Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) PET/Computerized tomography (CT) Sponsors: Ivan de Kouchkovsky, MD Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 25, 2024 Category: Research Source Type: clinical trials
Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial
Conditions: Recurrent Castration-Sensitive Prostate Carcinoma; Stage IVB Prostate Cancer AJCC v8; Recurrent Prostate Cancer; Castration-resistant Prostate Cancer Interventions: Drug: Abiraterone; Drug: Apalutamide; Procedure: Biospecimen Collection; Procedure: Bone Scan; Procedure: Computed Tomography; Drug: Darolutamide; Drug: Degarelix; Drug: Enzalutamide; Drug: Goserelin; Drug: Histrelin; Drug: Leuprolide; Procedure: Magnetic Resonance Imaging; Other: Patient Observation; Procedure: Positron Emission Tomography; Drug: Prednisone; Other: Questionnaire Administration; Drug: Relugolix; Radiation: Stereotactic Body Radiatio...
Source: ClinicalTrials.gov - April 23, 2024 Category: Research Source Type: clinical trials
Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHD
Conditions: cGVHD Interventions: Drug: anti-CD25 rhMAb; Drug: Prednisone; Drug: Ruxolitinib; Drug: Cyclosporine Sponsors: Peking University People ' s Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma
Conditions: Large B-cell Lymphoma Interventions: Drug: Golcadomide; Drug: Placebo; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Prednisone Sponsors: Celgene Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer
Conditions: Metastatic Prostate Cancer; Castration-resistant Prostate Cancer; Metastatic Castration-resistant Prostate Cancer Interventions: Drug: 177Lu-PSMA-617; Drug: Niraparib abiraterone acetate; Drug: Prednisone Sponsors: Rohan Garje; Janssen Scientific Affairs, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 26, 2024 Category: Research Source Type: clinical trials
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Conditions: Acute Leukemia of Ambiguous Lineage; B Acute Lymphoblastic Leukemia Interventions: Drug: Asparaginase Erwinia chrysanthemi; Procedure: Biospecimen Collection; Biological: Blinatumomab; Procedure: Bone Marrow Aspiration; Drug: Calaspargase Pegol; Procedure: Computed Tomography; Drug: Cyclophosphamide; Drug: Cytarabine; Drug: Daunorubicin; Drug: Dexamethasone; Drug: Doxorubicin; Procedure: Echocardiography; Procedure: FDG-Positron Emission Tomography; Drug: Leucovorin; Procedure: Lumbar Puncture; Procedure: Magnetic Resonance Imaging; Drug: Mercaptopurine; Drug: Methotrexate; Procedure: Multigated Acquisition Sca...
Source: ClinicalTrials.gov - March 19, 2024 Category: Research Source Type: clinical trials
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Conditions: Relapsed or Refractory Follicular Lymphoma Interventions: Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristine; Drug: Rituximab; Drug: Prednisone; Drug: Bendamustine; Drug: Lenalidomide; Drug: Fludarabine; Drug: Liso-cel Sponsors: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company; Celgene Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
Short-Term Versus 6-Week Prednisone in The Treatment of Subacute Thyroiditis
Conditions: Subacute Thyroiditis Interventions: Drug: 1-week predisone+1-week celecoxib; Drug: 6-weeks predisone Sponsors: Xinqiao Hospital of Chongqing Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
Conditions: Follicular Lymphoma Interventions: Drug: Mosunetuzumab; Drug: Lenalidomide; Drug: Rituximab; Drug: Obinutuzumab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Vincristin; Drug: Prednisone; Drug: Rituximab; Drug: Obinutuzumab; Drug: Bendamustin Sponsors: The Lymphoma Academic Research Organisation; Lymphoma Study Association; Swiss Group for Clinical Cancer Research; Grupo Espa ñol de Linfomas y Transplante Autólogo de Médula Ósea Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
Severe Erythema Multiforme - CORTICO
Conditions: Erythema Multiforme Interventions: Drug: Prednisone 20 Mg; Drug: Oral Placebo; Drug: Methylprednisolone 120 Mg; Drug: IV Placebo Sponsors: Assistance Publique - H ôpitaux de Paris Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 19, 2024 Category: Research Source Type: clinical trials
Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma
Conditions: B-cell Non-Hodgkin Lymphoma Interventions: Drug: Rocbrutinib; Biological: Rituximab; Drug: Cyclophosphamide; Drug: doxorubicin; Drug: Vincristin; Drug: Prednisone Sponsors: Guangzhou Lupeng Pharmaceutical Company LTD. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2024 Category: Research Source Type: clinical trials
Proof-of-concept to Evaluate the Efficacy and Safety of Prednisone in Idiosyncratic Hepatotoxicity
Conditions: Hepatotoxicity; Idiosyncratic Drug Effect; Prednisone Interventions: Drug: Prednisone Sponsors: Fundaci ón Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2024 Category: Research Source Type: clinical trials
Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma
Conditions: Diffuse Large B-Cell Lymphoma; High Grade B-Cell Lymphoma Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Bone Marrow Aspiration and Biopsy; Procedure: Computed Tomography; Drug: Cyclophosphamide; Drug: Doxorubicin; Procedure: Echocardiography; Drug: Etoposide; Procedure: Magnetic Resonance Imaging; Biological: Mosunetuzumab; Procedure: Multigated Acquisition Scan; Procedure: Positron Emission Tomography; Drug: Prednisone; Drug: Vincristine Sponsors: OHSU Knight Cancer Institute; Genentech, Inc.; Oregon Health and Science University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 8, 2024 Category: Research Source Type: clinical trials
the Effects of Different Treatment Schemes on Cognitive Function of Patients With Idiopathic Membranous Nephropathy
Conditions: Mild Cognitive Impairment; Idiopathic Membranous Nephropathy Interventions: Drug: prednisone,methylprednisone and cyclophosphamide; Drug: Rituximab Sponsors: Beijing Friendship Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL
Conditions: Acute Lymphoblastic Leukemia; Philadelphia Chromosome; Philadelphia-Positive ALL; Adult ALL; IKZF1 Gene Mutation Interventions: Drug: Prednisone, Olverembatinib, Blinatumomab, Chidamide Sponsors: Nanfang Hospital, Southern Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 24, 2024 Category: Research Source Type: clinical trials
